Katherine High, MD

Dr. Katherine High has enjoyed a 30+ year career in internal medicine, hematology, molecular genetics,
and gene therapy. She served as the inaugural director of a Center at The Children’s Hospital of
Philadelphia (CHOP) devoted to development of cell and gene therapies for diseases that affect the
pediatric population. At CHOP she was also an Investigator of the Howard Hughes Medical Institute. Dr.
High served a 5-year term on the U.S. FDA Advisory Committee on Cell, Tissue and Gene Therapies and is
a past president of the American Society of Gene & Cell Therapy. In 2013, she co-founded Spark
Therapeutics where she served as President, CSO, and member of the Board of Directors until Dec 2019
when Spark was acquired by Roche. Subsequently Dr. High left the organization, and in January 2021
joined AskBio, a wholly owned subsidiary of Bayer as President of Therapeutics and member of the
Board of Directors. In December 2022, she left AskBio to become a Visiting Professor at Rockefeller
University. Dr. High received her bachelor’s degree in chemistry from Harvard University, an MD from
the University of North Carolina School of Medicine, a business certification from the University of North
Carolina Business School’s Management Institute for Hospital Administrators and a master’s degree
from the University of Pennsylvania. She is an elected member of the National Academy of Medicine,
the American Academy of Arts and Sciences, the faculty of Pharmaceutical Medicine of the Royal College
of Physicians (London), and the National Academy of Sciences.